235 related articles for article (PubMed ID: 23134812)
21. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.
Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D
Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626
[TBL] [Abstract][Full Text] [Related]
22. Glial fibrillary acidic protein promoters direct adenovirus early 1A gene and human telomerase reverse transcriptase promoters direct sodium iodide symporter expression for malignant glioma radioiodine therapy.
Li W; Tan J; Wang P; Li N; Li C
Mol Cell Biochem; 2015 Jan; 399(1-2):279-89. PubMed ID: 25410753
[TBL] [Abstract][Full Text] [Related]
23. An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.
Lal S; Carrera D; Phillips JJ; Weiss WA; Raffel C
Neuro Oncol; 2018 Nov; 20(12):1606-1615. PubMed ID: 29912438
[TBL] [Abstract][Full Text] [Related]
24.
Jung MY; Offord CP; Ennis MK; Kemler I; Neuhauser C; Dingli D
Cancer Res; 2018 Oct; 78(20):5992-6000. PubMed ID: 30115692
[TBL] [Abstract][Full Text] [Related]
25. Treatment of medulloblastoma with a modified measles virus.
Studebaker AW; Kreofsky CR; Pierson CR; Russell SJ; Galanis E; Raffel C
Neuro Oncol; 2010 Oct; 12(10):1034-42. PubMed ID: 20494960
[TBL] [Abstract][Full Text] [Related]
26. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
Mitrofanova E; Unfer R; Vahanian N; Link C
Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
28. Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.
Mansfield DC; Kyula JN; Rosenfelder N; Chao-Chu J; Kramer-Marek G; Khan AA; Roulstone V; McLaughlin M; Melcher AA; Vile RG; Pandha HS; Khoo V; Harrington KJ
Gene Ther; 2016 Apr; 23(4):357-68. PubMed ID: 26814609
[TBL] [Abstract][Full Text] [Related]
29. Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors.
Dwyer RM; Bergert ER; O'Connor MK; Gendler SJ; Morris JC
Hum Gene Ther; 2006 Jun; 17(6):661-8. PubMed ID: 16776574
[TBL] [Abstract][Full Text] [Related]
30. Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.
Trujillo MA; Oneal MJ; Davydova J; Bergert E; Yamamoto M; Morris JC
Breast Cancer Res; 2009; 11(4):R53. PubMed ID: 19635153
[TBL] [Abstract][Full Text] [Related]
31. In vivo molecular imaging and radionuclide (131I) therapy of human nasopharyngeal carcinoma cells transfected with a lentivirus expressing sodium iodide symporter.
Shi S; Zhang M; Guo R; Miao Y; Hu J; Xi Y; Li B
PLoS One; 2015; 10(1):e0116531. PubMed ID: 25621996
[TBL] [Abstract][Full Text] [Related]
32. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter.
Spitzweg C; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC
Cancer Res; 2000 Nov; 60(22):6526-30. PubMed ID: 11103823
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery.
Müller AM; Schmohl KA; Knoop K; Schug C; Urnauer S; Hagenhoff A; Clevert DA; Ingrisch M; Niess H; Carlsen J; Zach C; Wagner E; Bartenstein P; Nelson PJ; Spitzweg C
Oncotarget; 2016 Aug; 7(34):54795-54810. PubMed ID: 27458162
[TBL] [Abstract][Full Text] [Related]
34. Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography.
Penheiter AR; Dingli D; Bender CE; Russell SJ; Carlson SK
J Gene Med; 2012; 14(9-10):590-7. PubMed ID: 23015290
[TBL] [Abstract][Full Text] [Related]
35. Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors.
Penheiter AR; Griesmann GE; Federspiel MJ; Dingli D; Russell SJ; Carlson SK
Gene Ther; 2012 Mar; 19(3):279-87. PubMed ID: 21753796
[TBL] [Abstract][Full Text] [Related]
36. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
37. Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter.
Huang R; Zhao Z; Ma X; Li S; Gong R; Kuang A
Cancer Gene Ther; 2011 Feb; 18(2):144-52. PubMed ID: 21037556
[TBL] [Abstract][Full Text] [Related]
38. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy.
Boland A; Ricard M; Opolon P; Bidart JM; Yeh P; Filetti S; Schlumberger M; Perricaudet M
Cancer Res; 2000 Jul; 60(13):3484-92. PubMed ID: 10910060
[TBL] [Abstract][Full Text] [Related]
39. Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy.
Renier C; Do J; Reyna-Neyra A; Foster D; De A; Vogel H; Jeffrey SS; Tse V; Carrasco N; Wapnir I
Oncotarget; 2016 Aug; 7(34):54811-54824. PubMed ID: 27363025
[TBL] [Abstract][Full Text] [Related]
40. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.
Myers RM; Greiner SM; Harvey ME; Griesmann G; Kuffel MJ; Buhrow SA; Reid JM; Federspiel M; Ames MM; Dingli D; Schweikart K; Welch A; Dispenzieri A; Peng KW; Russell SJ
Clin Pharmacol Ther; 2007 Dec; 82(6):700-10. PubMed ID: 17971816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
